Skip to main content
. 2019 Apr 25;43:261–269. doi: 10.1016/j.ebiom.2019.04.003

Fig. 2.

Fig. 2

Changes in ctDNA, imaging, and serum biomarker during progressive disease in patient P19. (A) CT: Imaging shows new metastasis in lung and liver. Therapy: treatment strategies and procedures. Sampling date: ctDNA sampled at baseline, the second treatment cycle, and when disease progressed. Characteristics of molecular clones: The diagram illustrates clone structure and selection in serial ctDNA. CEA: The levels of CEA increased during treatment. (B) Mutations identified in serial ctDNA. CEA, carcinoembryonic antigen; XP, capecitabine (xeloda)/cis‑platinum; T, trastuzumab; P, cis‑platinum; VAF, variated allele frequency.